Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Erosive Hand Osteoarthritis
NCT02771860Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Mar 2016
- Primary completion
- Jun 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of denosumab in erosive osteoarthritis (EOA) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Total Ghent University Scoring System of Target Joints at 24 weeks. Started Mar 2016; status: completed.
02
Drugs
denosumab
03
Conditions
erosive osteoarthritis (EOA)
Beyond the preview
Go deeper on NCT02771860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771860.